More than 5 years of European Paediatric Regulation: Statistics and industrial experience

International Journal of Pharmaceutics

Volumn 469, Issue 2, 2014, Pages 260-262

  Winzenburg, Gesine ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG; DRUG DOSAGE FORM;

ARTICLE; DRUG LEGISLATION; HUMAN; PEDIATRIC INVESTIGATION PLAN; PEDIATRICS; PRIORITY JOURNAL; REGISTRATION; CHILD; DRUG DOSAGE FORM; DRUG INDUSTRY; EUROPEAN UNION; LEGISLATION AND JURISPRUDENCE;

CHILD; DOSAGE FORMS; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; EUROPEAN UNION; HUMANS; LEGISLATION, DRUG; PEDIATRICS;

EID: 84902271428     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2014.03.058     Document Type: Article

References (13)

1. J. Breitkreutz, and J. Boos Paediatric and geriatric drug delivery Expert Opinion on Drug Delivery 4 2007 37 45 (Pubitemid 46117485)
2. Committee for Medicinal Products for Human Use, EMA, 2006: Reflection paper: formulation of choice for the paediatric population (http://www.ema. europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003782. pdf). (assessed 08.12.13.).
3. Committee for Medicinal Products for Human Use, EMA, 2007: guideline on excipients in the dossier for application for marketing authorisation of a medicinal product (http://www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2009/09/WC500003382.pdf). (assessed 08.12.13.).
4. Committee for Medicinal Products for Human Use, EMA, 2008: guideline on the need founon-clinical testing in juvenile animals of pharmaceuticals for paediatric use (http://www.ema.europa.eu/docs/en-GB/document-library/Scientific- guideline/2009/09/WC500003305.pdf). (assessed 08.12.12.).
5. Creba, J., Johnson, C., Joos, A., 2011. EFPIA survey on impact of the paediatric regulation on marketing authorization holders (Jan 2007-June 2010). EMA-EFPIA information day (http://www.ema.europa.eu/docs/en-GB/document-library/ Presentation/2011/05/WC500106718.pdf). (assessed 08.12.13.).
6. Request for modification of an agreed paediatric investigation plan (http://www.ema.europa.eu/docs/en-GB/document-library/Template-or-form/2013/09/ WC500148544.pdf). (assessed 08.12.13.).
7. Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December (2006) on Medicinal Products for Paediatric Use (http://ec.europa.eu/health/files/eudralex/vol-1/reg-2006-1901/reg-2006-1901-en. pdf). (accessed 08.12.13.).
8. 5-year Report to the European Commission. General report on the experience acquired as a result of the application of the Paediatric Regulation (http://ec.europa.eu/health/files/paediatrics/2012-09-paediatric-report-annex1- 2-en.pdf). (accessed 08.12.13.).
9. Better Medicines for Children From Concept to Reality. General report on the experience acquired as a result of the application of the Paediatric Regulation (EC) N° 1901/2006 on medicinal products for paediatric use (http://ec.europa.eu/health/files/paediatrics/2013-com443/paediatric-report- com(2013)443-en.pdf). (assessed 08.12.13.).
10. Guideline on pharmaceutical development of medicines for paediatric use (http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2013/ 07/WC500147002.pdf).(assessed 08.12.13.).
11. B.S. Lima, M.D. Theilade-Thomsen, J. Carleer, J.M. Vidal, P. Tomasi, and A. Saint-Raymond Juvenile animal studies for the development of paediatric medicines: a description and conclusions from a European medicines agency workshop on juvenile animal testing for nonclinical assessors Birth Defects Research 89 2010 467 473
12. B. Quijano Ruiz, E. Desfontaine, S. Arenas-Lopez, and S. Wanh Pediatric formulation issues identified in pediatric investigation plans Expert Review of Clinical Pharmacology 7 2014 25 30
13. J. Rawcliffe, J. Winslade, and S.E. Conroy Buccolam: the first centralized paediatric use marketing authorization International Journal of Pharmaceutics 457 2013 348 350